Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

Description

The purpose of the research is to determine whether a class of medication called SGLT2 inhibitor will improve the heart's function and reduce its enlargement after a heart attack. Participation in this study will involve taking this class of medication (or a placebo) once daily for six months, one cardiac magnetic resonance imaging (MRI) test during your initial hospitalization, follow-up phone calls at 1 and 3 months, and one cardiac MRI and clinic visit at six months. This is a single center study.

Conditions

Heart Attack, Enlarged Heart

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of the research is to determine whether a class of medication called SGLT2 inhibitor will improve the heart's function and reduce its enlargement after a heart attack. Participation in this study will involve taking this class of medication (or a placebo) once daily for six months, one cardiac magnetic resonance imaging (MRI) test during your initial hospitalization, follow-up phone calls at 1 and 3 months, and one cardiac MRI and clinic visit at six months. This is a single center study.

Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition Improves Left Ventricular Function and Reduces Adverse Left-Ventricular Remodeling in High-Risk Patients with Microvascular Obstruction (MVO) Following ST-elevation Myocardial Infarction (STEMI).

Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

Condition
Heart Attack
Intervention / Treatment

-

Contacts and Locations

Minneapolis

Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States, 55407

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients with their first STEMI (\>18 years) who underwent successful primary PCI and able to give informed consent
  • * At least mild LV dysfunction (LVEF \< 50%) on echocardiogram, cMRI or Left Ventriculargram following PCI
  • * Infarct size that is \> 10% of LV mass
  • * The presence of MVO that is \> 10% of infarct size
  • * Contraindication to cardiac MRI
  • * Life expectancy \< 1 year
  • * Previous CABG or Valve Surgery
  • * Previous STEMI
  • * Pregnant or planning to become pregnant or lactating women
  • * Cardiogenic shock (not resolved)
  • * Atrial fibrillation or recurrent sustained ventricular arrhythmias (excluding PVCs)
  • * GFR\<30 ml/min/1.73m2 or end-stage renal disease on dialysis
  • * Type 1 diabetes mellitus or history of diabetic ketoacidosis
  • * Type I or II diabetes with insulin use
  • * Prior intolerance of SGLT2 inhibitors
  • * Current use of SGLT2 inhibitors (randomized patients only)
  • * Contraindications to gadolinium

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Minneapolis Heart Institute Foundation,

Jay Traverse, MD, PRINCIPAL_INVESTIGATOR, Minneapolis Heart Institute Foundation

Study Record Dates

2028-12